EMA accepts to review Mylan and Biocon’s cancer biosimilar
The European Medicines Agency (EMA) will reviewMylan and Biocon‘s marketing authorisation application (MAA) for their proposed trastuzumab biosimilar, used to treat certain HER2-positive breast and gastric cancers.
Click on this link for more information.
